2. GPCR/G Protein MAPK/ERK Pathway Stem Cell/Wnt PI3K/Akt/mTOR NF-κB Metabolic Enzyme/Protease Immunology/Inflammation Apoptosis
  3. Ras ERK Akt Reactive Oxygen Species (ROS) Apoptosis Bcl-2 Family Caspase
  4. KRAS G12D-IN-37

KRAS G12D-IN-37 is a KRASG12D inhibitor. KRAS G12D-IN-37 shows antiproliferative activity against KRASG12D mutant tumor cells and minimal cytotoxicity toward normal cells. KRAS G12D-IN-37 binds stably to KRASG12D via hydrogen bond interactions with residues His 95, Arg 68, and Asp 12, and inhibits downstream ERK/AKT signaling pathways. KRAS G12D-IN-37 elevates ROS levels, induces apoptosis, disrupts mitochondrial membrane potential. KRAS G12D-IN-37 downregulates the level of anti-apoptotic protein Bcl-2, and upregulates the levels of pro-apoptotic proteins Bax and caspase 3. KRAS G12D-IN-37 can be used for the research of cancer, such as gastric adenocarcinoma and colorectal cancer.

For research use only. We do not sell to patients.

KRAS G12D-IN-37

KRAS G12D-IN-37 Chemical Structure

Size Stock
50 mg   Get quote  
100 mg   Get quote  
250 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

KRAS G12D-IN-37 Related Antibodies

Top Publications Citing Use of Products

View All Ras Isoform Specific Products:

View All Isoforms
K-Ras H-Ras N-Ras Ras

View All ERK Isoform Specific Products:

View All Isoforms
ERK ERK1 ERK2 ERK5 ERK8

View All Akt Isoform Specific Products:

View All Isoforms
Akt Akt1 Akt2 Akt3

View All Bcl-2 Family Isoform Specific Products:

View All Isoforms
Bcl-2 Bcl-xL Bcl-W Mcl-1 Bfl-1 Bcl-B Bax Bak Bim BNIP3 Bad

View All Caspase Isoform Specific Products:

View All Isoforms
Caspase 1 Caspase 2 Caspase 3 Caspase 4 Caspase 5 Caspase 6 Caspase 7 Caspase 8 Caspase 9 Caspase 10 Caspase 12 Caspase Caspase 11 Caspase-13

  • Biological Activity

  • Purity & Documentation

  • References

  • Customer Review

Description

KRAS G12D-IN-37 is a KRASG12D inhibitor. KRAS G12D-IN-37 shows antiproliferative activity against KRASG12D mutant tumor cells and minimal cytotoxicity toward normal cells. KRAS G12D-IN-37 binds stably to KRASG12D via hydrogen bond interactions with residues His 95, Arg 68, and Asp 12, and inhibits downstream ERK/AKT signaling pathways. KRAS G12D-IN-37 elevates ROS levels, induces apoptosis, disrupts mitochondrial membrane potential. KRAS G12D-IN-37 downregulates the level of anti-apoptotic protein Bcl-2, and upregulates the levels of pro-apoptotic proteins Bax and caspase 3. KRAS G12D-IN-37 can be used for the research of cancer, such as gastric adenocarcinoma and colorectal cancer[1].

IC50 & Target[1]

KRas G12D

 

Bcl-2

 

Bax

 

Caspase 3

 

In Vitro

KRAS G12D-IN-37 (Compound 16k) (72 h) potently inhibits the proliferation of KRASG12D-mutant AGS and GP2D cells with IC50 values of 0.18 μM and 0.21 μM, respectively, while showing lower activity against other KRAS mutant cells, KRAS wild-type cells, and normal HIEC cells[1].
KRAS G12D-IN-37 (0.31-2.5 μM; 24-72 h) exhibits time-dependent cytotoxicity against KRASG12D-mutant AGS and GP2D cells[1].
KRAS G12D-IN-37 (0.0625-0.5 μM; 14 days) potently inhibits the colony formation of KRASG12D-mutant AGS and GP2D cells in a dose-dependent manner[1].
KRAS G12D-IN-37 (0.625-2.5 μM; 6 h) inhibits the downstream ERK/AKT signaling pathways of KRAS in KRASG12D-mutant AGS and GP2D cells, reducing p-ERK and p-AKT levels in a dose-dependent manner[1].
KRAS G12D-IN-37 (0.625-2.5 μM; 24 h) dose-dependently enhances intracellular ROS accumulation and disrupts mitochondrial membrane potential in KRASG12D-mutant AGS and GP2D cells[1].
KRAS G12D-IN-37 (0.625-5 μM; 24 h) dose-dependently induces apoptosis in KRASG12D-mutant AGS and GP2D cells, dose-dependently altering the balance of pro- and anti-apoptotic proteins and increasing Caspase 3 activity[1].
KRAS G12D-IN-37 (1 μM) demonstrates favorable metabolic stability in rat liver microsomes, with a half-life of 289 min[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

KRAS G12D-IN-37 Related Antibodies

Cell Proliferation Assay[1]

Cell Line: KRAS G12D-mutant AGS and GP2D cells
Concentration: 0.0625, 0.125, 0.25, 0.5 μM
Incubation Time: 14 days (medium changes every 72 h)
Result: Dose-dependently inhibited colony formation of AGS and GP2D cells.
Almost entirely suppressed AGS cell colony formation at 0.25 μM; almost entirely suppressed GP2D cell colony formation at 0.5 μM.
Showed superior colony formation inhibition efficacy compared to MRTX 1133 (HY-134813).

Western Blot Analysis[1]

Cell Line: KRAS G12D-mutant AGS and GP2D cells
Concentration: 0.625, 1.25, 2.5 μM
Incubation Time: 6 h
Result: Decreased the phosphorylation of ERK and AKT in AGS and GP2D cells.
Reduced p-AKT levels by 90% and p-ERK levels by 70% in GP2D cells at 2.5 μM; the effect on p-AKT/AKT was comparable to that of MRTX 1133.
Caused p-ERK levels to rebound at 1.25 μM in GP2D cells, potentially due to negative feedback in RAS signaling.

Apoptosis Analysis[1]

Cell Line: KRAS G12D-mutant AGS and GP2D cells
Concentration: 0.625, 1.25, 2.5 μM
Incubation Time: 24 h
Result: Induced apoptosis in AGS and GP2D cells in a dose-dependent manner.
Induced apoptosis in 80% of AGS cells at 5 μM; induced apoptosis in a high proportion of GP2D cells at 2.5 μM.
Induced higher apoptosis rates than MRTX 1133, with most apoptotic events occurring in the early stage.

Western Blot Analysis[1]

Cell Line: KRAS G12D-mutant AGS and GP2D cells
Concentration: 0.625, 1.25, 2.5 μM
Incubation Time: 24 h
Result: Dose-dependently upregulated the levels of pro-apoptotic proteins Bax and Caspase 3, and downregulated the level of anti-apoptotic protein Bcl-2 in AGS and GP2D cells.
Dose-dependently increased Caspase 3 activity in both cell lines.
In Vivo

KRAS G12D-IN-37 (Compound 16k) (500-1500 mg/kg; p.o.; single dose) exhibits a favorable in vivo safety profile in Kunming mice, with an LD50 of approximately 1270 mg/kg[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: Healthy Kunming mice (equally divided by sex)[1]
Dosage: 1500 mg/kg; 1200 mg/kg; 1000 mg/kg; 500 mg/kg
Administration: p.o.; single dose
Result: Caused death of all mice at 1500 mg/kg.
Led to death of 2 of 6 mice at 1200 mg/kg, with a calculated median lethal dose (LD50) of approximately 1270 mg/kg.
Showed no notable weight loss or physical abnormalities in mice treated with 500 mg/kg or 1000 mg/kg over 14 days.
Revealed no significant morphological changes or cellular abnormalities in heart, liver, spleen, lungs, and kidneys of mice treated with 1000 mg/kg.
Molecular Weight

557.61

Formula

C29H34F3N5O3
SMILES

FC(C1=CC=C(OC)C(C2=CC3=NC(OC[C@H]4CCCN4C)=NC(N5C[C@H](N6)CC[C@H]6C5)=C3C=C2OC)=C1)(F)F
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
References
  • No file chosen (Maximum size is: 1024 Kb)
  • If you have published this work, please enter the PubMed ID.
  • Your name will appear on the site.

KRAS G12D-IN-37 Related Classifications

  • Molarity Calculator

  • Dilution Calculator

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass   Concentration   Volume   Molecular Weight *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

KRAS G12D-IN-37RasERKAktReactive Oxygen Species (ROS)ApoptosisBcl-2 FamilyCaspaseExtracellular signal regulated kinasesPKBProtein kinase BAGS cellsERK/AKT signaling pathwaysapoptosisHIEC cellsKunming micegastric adenocarcinomaKRAS G12Dreactive oxygen speciesGP2D cellscolorectal cancerInhibitorinhibitorinhibit

Your Recently Viewed Products:

Inquiry Online

Your information is safe with us. * Required Fields.

Product Name

  

Requested Quantity *

Applicant Name *

 

Salutation

Email Address *

 

Phone Number *

Department

 

Organization Name *

City

State

Country or Region *

      

Remarks

Bulk Inquiry

Inquiry Information

Product Name:
KRAS G12D-IN-37
Cat. No.:
HY-183355
Quantity:
MCE Japan Authorized Agent:

Customer Review

Thank You for Your Feedback!

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

Product Name

  

Lot #

Applicant Name *

 

Email Address *

Phone Number

 

Department *

Organization Name *

 

Country or Region *

Remarks

SAFETY DATA SHEET (SDS)

Request for HNMR Report

We have received your request and will respond to you as soon as possible.